Virginia M Klimek MD

Oncology•New York, NY

Assistant Professor, Medicine, Weill Cornell Medical College

Join to View Full Profile

1275 York AveNew York, NY 10065
Phone+1 212-639-2000

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1994

Certifications & Licensure

NC State Medical License 2020 - 2022
NY State Medical License 1995 - 2022
NJ State Medical License 2015 - 2021

Clinical Trials

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Start of enrollment: 1999 Aug 01
Completed
Phase 1
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma Start of enrollment: 2002 May 01
Completed
Phase 2
An Open-Label, Phase II (Proof Of Concept) Trial Of PKC412 Monotherapy In Patients With Acute Myeloid Leukemia (AML) And Patients With High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2002 Mar 01
A Multicenter, Single-Arm, Open-Label Study Of The Efficacy And Safety Of CC-5013 Monotherapy In RBC Transfusion-Dependent Subjects With Myelodysplastic Syndromes Start of enrollment: 2003 Sep 01
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 Jul 01
Completed
Phase 1, Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
ACTIVE_NOT_RECRUITING
PHASE3
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Mar 01
Withdrawn
Phase 1, Phase 2
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Start of enrollment: 2011 May 01
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes Start of enrollment: 2014 Aug 27
Completed
Phase 2
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors Start of enrollment: 2017 Aug 07
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

7 citations
Molecular taxonomy of myelodysplastic syndromes and its clinical implications.
Elsa Bernard, Robert P Hasserjian, Peter L Greenberg, Juan E Arango Ossa, Maria Creignou
Blood. 2024-10-10
15 citations
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina
Blood. 2024-09-12
8 citations
Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Tulasigeri M Totiger, Sana Chaudhry, Elgilda Musi, Jumana Afaghani, Skye Montoya
Journal of Cellular and Molecular Medicine. 2023-02-01

Journal Articles

End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center
Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)
Virginia M. Klimek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018